Valuation: Exelixis, Inc.

Market Cap 13.56B 11.85B 10.88B 10.15B 19.24B 1,291B 19.56B 131B 50.78B 633B 50.93B 49.82B 2,182B P/E 2026 *
17x
P/E 2027 * 14.6x
Enterprise Value 12.79B 11.18B 10.27B 9.57B 18.15B 1,218B 18.45B 124B 47.9B 597B 48.04B 46.99B 2,058B EV / Sales 2026 *
4.92x
EV / Sales 2027 * 4.05x
Free-Float
98.18%
Yield 2026 *
-
Yield 2027 * -
1 day+1.70%
1 week+3.05%
Current month+0.82%
1 month+13.01%
3 months+25.01%
6 months+25.87%
Current year+25.15%
1 week 53.08
Extreme 53.075
56.21
1 month 48.1
Extreme 48.1036
56.21
Current year 39.71
Extreme 39.71
56.21
1 year 33.76
Extreme 33.755
56.21
3 years 18.64
Extreme 18.64
56.21
5 years 14.87
Extreme 14.87
56.21
10 years 7.93
Extreme 7.93
56.21
Manager TitleAgeSince
Chief Executive Officer 65 22/07/2010
Director of Finance/CFO 58 15/07/2015
Chief Operating Officer 63 01/02/2016
Director TitleAgeSince
Director/Board Member 70 01/02/2004
Director/Board Member 82 01/08/2004
Chairman 77 01/01/1998
Date Insider Type Main position Quantity % Market Cap.
06-01Sell

Director

-9,812 0.0039%
06-01Sell

Director

-3,925 0.0016%
05-27Free

Director

8,367 0.0033%
Change 5-day change 1-year change 3-year change Capi.($)
+1.78%+3.05%+23.83%+186.75% 13.56B
+3.98%+5.55%+76.40%+136.18% 56.21B
-3.12%+5.11%+71.57%+94.67% 55.38B
+2.93%+7.44%-10.68%-10.31% 23.75B
+2.10%+4.54%+11.17%+426.34% 23.19B
+3.64%+10.54%+39.81%-4.50% 18.14B
+4.11%+8.89%+44.60%-27.73% 16.84B
+2.57%+20.26%+181.98%+355.99% 15.86B
+7.20%+10.70%+42.91% - 12.97B
+1.92%+1.82%+74.30%+131.71% 11.86B
Average +2.69%+6.61%+55.59%+143.23% 24.78B
Weighted average by Cap. +1.95%+5.84%+58.05%+135.15%

Financials

2026 *2027 *
Net sales 2.6B 2.27B 2.09B 1.95B 3.69B 247B 3.75B 25.11B 9.73B 121B 9.76B 9.55B 418B 2.92B 2.55B 2.34B 2.19B 4.15B 278B 4.22B 28.23B 10.94B 136B 10.97B 10.73B 470B
Net income 818M 715M 657M 612M 1.16B 77.9B 1.18B 7.91B 3.06B 38.21B 3.07B 3.01B 132B 934M 816M 750M 699M 1.33B 88.94B 1.35B 9.03B 3.5B 43.63B 3.51B 3.43B 150B
Net Debt -770M -673M -618M -576M -1.09B -73.31B -1.11B -7.44B -2.88B -35.96B -2.89B -2.83B -124B -1.73B -1.51B -1.39B -1.3B -2.46B -165B -2.5B -16.72B -6.48B -80.83B -6.5B -6.36B -279B
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Employees
1,077
Date Price Change Volume
03/07/26 US$54.83 +1.61% 841,639
01/07/26 US$53.96 -0.83% 1,843,248
30/06/26 US$54.41 +0.24% 2,599,397
29/06/26 US$54.28 -0.89% 2,587,750
26/06/26 US$54.77 +2.89% 6,931,468
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
53.96USD
Average target price
49.50USD
Spread / Average Target
-8.27%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EXEL Stock